×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EPRX – eupraxia pharmaceuticals inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EPRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/19
06:20 am
eprx
Eupraxia Pharmaceuticals (EPRX) was downgraded by Zacks Research from "hold" to "strong sell".
Low
Report
Eupraxia Pharmaceuticals (EPRX) was downgraded by Zacks Research from "hold" to "strong sell".
3/17
08:29 am
eprx
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis [Yahoo! Finance]
3/17
08:01 am
eprx
Eupraxia Pharmaceuticals (EPRX) had its price target lowered by HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Eupraxia Pharmaceuticals (EPRX) had its price target lowered by HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.
3/17
07:00 am
eprx
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Medium
Report
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
3/12
09:03 pm
eprx
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Low
Report
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
2/20
03:50 pm
eprx
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option [Yahoo! Finance]
Low
Report
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/17
07:00 am
eprx
Form 6-K EUPRAXIA PHARMACEUTICALS For: Mar 17
Medium
Report
Form 6-K EUPRAXIA PHARMACEUTICALS For: Mar 17
3/16
09:57 pm
eprx
Form SCHEDULE 13D/A EUPRAXIA PHARMACEUTICALS Filed by: Freedman Joseph S.
Medium
Report
Form SCHEDULE 13D/A EUPRAXIA PHARMACEUTICALS Filed by: Freedman Joseph S.
3/13
06:04 am
eprx
Form 40-F EUPRAXIA PHARMACEUTICALS For: Dec 31
Low
Report
Form 40-F EUPRAXIA PHARMACEUTICALS For: Dec 31
3/6
01:58 pm
eprx
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 23
Low
Report
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 23
2/20
03:21 pm
eprx
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 20
Low
Report
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 20
2/20
06:01 am
eprx
Form SUPPL EUPRAXIA PHARMACEUTICALS
Medium
Report
Form SUPPL EUPRAXIA PHARMACEUTICALS
2/20
06:00 am
eprx
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 19
Medium
Report
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 19
2/19
06:05 am
eprx
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 19
Medium
Report
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 19
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: